Koronis Pharmaceuticals is a

Seattle Seattle ( ) is a seaport city on the West Coast of the United States. It is the seat of King County, Washington. With a 2020 population of 737,015, it is the largest city in both the state of Washington and the Pacific Northwest regio ...

area

biotechnology Biotechnology is the integration of natural sciences and engineering sciences in order to achieve the application of organisms, cells, parts thereof and molecular analogues for products and services. The term ''biotechnology'' was first used b ...

company founded in 1998. Koronis is dedicated to the development of

antiviral Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Unlike most antibiotics, antiviral drugs do no ...

therapeutics based on a novel mechanism, Viral Decay Acceleration (VDA). The Company's lead product candidate is

KP-1461 KP-161 is an experimental antiviral drug being studied for the treatment of HIV/AIDS. It belongs to the class of nucleoside reverse transcriptase inhibitor Reverse-transcriptase inhibitors (RTIs) are a class of antiretroviral drugs used to treat ...

for the treatment of human immunodeficiency virus (HIV) infection. The company also has products in development for the treatment of

hepatitis C Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; it is a type of viral hepatitis. During the initial infection people often have mild or no symptoms. Occasionally a fever, dark urine, a ...

and RSV infection.

References

* * * * * Paulson, Tom. "Conflicts Advance a Burgeoning Field Industry, Academia Now are Bedfellows." Seattle P-I. May 19, 1999: A1. * Biotech Industry Driven By Evolution Searching For Cures, Companies Get Creative. Carol Smith P-I Reporter. Seattle P-I. May 17, 1999: A1. * Mature companies beat out new ones for VC cash. Romano, Benjamin J. Seattle Times. October 25, 2005: C1. * *

External links

* * Reuters story on IPO prospect

Biotechnology companies of the United States Companies based in Seattle {{med-company-stub